Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EADO 2018 /
Brain metastases: therapeutic options

6th - 9th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.18
Views: 433

Prof Brigette Dréno - University Hospital Nantes, Nantes, France

Prof Brigette Dréno speaks with ecancer at the EADO 2018 congress in Barcelona about the different therapies for targeting brain metastases.

Prof Dréno explains that the combination therapy of anti PD-1 and ipilimumab immunotherapy is the best treatment for brain metastases.

He explains that for patients with a metastatic disease such as isolated systemic metastasis similar results or better can be achieved through surgery.

She acknowledges the toxicity of this therapy but that it is often only an initial reaction and that severe adverse events could be linked to a clinical response.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation